In selected HBL cases with a predominantly fetal cell component, intense EGFR expression may present a rationale for using EGFR inhibitors as an alternative to cisplatin and Adriamycin, which can be ototoxic and cardiotoxic, respectively, and are current first-line drugs for HBL4, 44, 45. Here, EGFR is linked to hepatoblastoma.